Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Payables (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Payables data on record, last reported at $45.5 million in Q4 2025.

  • For Q4 2025, Payables fell 85.05% year-over-year to $45.5 million; the TTM value through Dec 2025 reached $45.5 million, down 85.05%, while the annual FY2025 figure was $45.5 million, 85.05% down from the prior year.
  • Payables reached $45.5 million in Q4 2025 per PTCT's latest filing, down from $303.1 million in the prior quarter.
  • Across five years, Payables topped out at $392.0 million in Q4 2023 and bottomed at $13.3 million in Q3 2024.
  • Average Payables over 5 years is $184.5 million, with a median of $229.0 million recorded in 2021.
  • Peak YoY movement for Payables: plummeted 96.41% in 2024, then skyrocketed 2180.63% in 2025.
  • A 5-year view of Payables shows it stood at $23.0 million in 2021, then surged by 1290.9% to $320.4 million in 2022, then grew by 22.35% to $392.0 million in 2023, then fell by 22.37% to $304.3 million in 2024, then tumbled by 85.05% to $45.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $45.5 million in Q4 2025, $303.1 million in Q3 2025, and $338.9 million in Q2 2025.